成功取栓后动脉内阿替普酶与安慰剂对急性大血管闭塞性缺血性卒中患者功能结局的影响:CHOICE随机临床试验
该2b期随机双盲安慰剂对照试验在西班牙加泰罗尼亚7个卒中中心纳入121例大血管闭塞急性缺血性卒中患者,取栓成功后分别接受动脉内阿替普酶(0.225 mg/kg,最大22.5 mg)或安慰剂。90天改良Rankin量表评分0或1分的比例阿替普酶组为59.0%(36/61),安慰剂组为40.4%(21/52),校正风险差18.4%(95%CI 0.3%-36.4%;P=0.047)。作者认为结果属初步发现,需重复验证。
要点
- 取栓成功再通后动脉内阿替普酶组90天mRS 0-1分比例为59.0%(36/61),安慰剂组为40.4%(21/52)。
- 校正风险差为18.4%(95%CI 0.3%-36.4%;P=0.047),作者认为属初步发现,需重复验证。
- 症状性颅内出血24小时内阿替普酶组0%,安慰剂组3.8%(风险差-3.8%;95%CI -13.2%至2.5%)。
核心结论
- 在大血管闭塞急性缺血性卒中取栓成功再通的患者中,与安慰剂相比,辅助动脉内阿替普酶使90天优良神经功能结局的可能性更高,但作者指出因研究局限性,这些发现应视为初步结果并需重复验证。
研究设计与样本
- 2b期随机、双盲、安慰剂对照试验,2018年12月至2021年5月在西班牙加泰罗尼亚7个卒中中心进行。
- 纳入121例大血管闭塞急性缺血性卒中患者,卒中发作24小时内接受取栓且脑缺血扩展治疗血管造影评分为2b50至3。
- 参与者随机接受动脉内阿替普酶(0.225 mg/kg;最大剂量22.5 mg)15至30分钟输注(n=61)或安慰剂(n=52)。
- 主要结局为按随机分组治疗的全部患者90天改良Rankin量表评分为0或1分的比例差异。
主要发现
- 90天改良Rankin量表评分0或1分的比例:阿替普酶组59.0%(36/61)vs 安慰剂组40.4%(21/52),校正风险差18.4%(95%CI 0.3%-36.4%;P=0.047)。
- 24小时内症状性颅内出血比例:阿替普酶组0% vs 安慰剂组3.8%,风险差-3.8%(95%CI -13.2%至2.5%)。
- 90天死亡率:阿替普酶组8% vs 安慰剂组15%,风险差-7.2%(95%CI -19.2%至4.8%)。
- 研究因无法维持安慰剂供应及COVID-19大流行导致入组率不足而提前终止。
临床怎么用
- 作者认为,在大血管闭塞急性缺血性卒中取栓成功再通的患者中,辅助动脉内阿替普酶相比安慰剂使90天优良神经功能结局的可能性更高,但因研究局限性,这些发现应视为初步结果并需重复验证。
局限性
- 研究因无法维持安慰剂供应及COVID-19大流行导致入组率不足而提前终止。
- 作者指出因研究局限性,这些发现应视为初步结果并需重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is estimated that only 27% of patients with acute ischemic stroke and large vessel occlusion who undergo successful reperfusion after mechanical thrombectomy are disability free at 90 days. An incomplete microcirculatory reperfusion might contribute to these suboptimal clinical benefits. OBJECTIVE: To investigate whether treatment with adjunct intra-arterial alteplase after thrombectomy improves outcomes following reperfusion. DESIGN, SETTING, AND PARTICIPANTS: Phase 2b randomized, double-blind, placebo-controlled trial performed from December 2018 through May 2021 in 7 stroke centers in Catalonia, Spain. The study included 121 patients with large vessel occlusion acute ischemic stroke treated with thrombectomy within 24 hours after stroke onset and with an expanded Treatment in Cerebral Ischemia angiographic score of 2b50 to 3. INTERVENTIONS: Participants were randomized to receive intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes (n = 61) or placebo (n = 52). MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in proportion of patients achieving a score of 0 or 1 on the 90-day modified Rankin Scale (range, 0 [no symptoms] to 6 [death]) in all patients treated as randomized. Safety outcomes included rate of symptomatic intracranial hemorrhage and death. RESULTS: The study was terminated early for inability to maintain placebo availability and enrollment rate because of the COVID-19 pandemic. Of 1825 patients with acute ischemic stroke treated with thrombectomy at the 7 study sites, 748 (41%) patients fulfilled the angiographic criteria, 121 (7%) patients were randomized (mean age, 70.6 [SD, 13.7] years; 57 women [47%]), and 113 (6%) were treated as randomized. The proportion of participants with a modified Rankin Scale score of 0 or 1 at 90 days was 59.0% (36/61) with alteplase and 40.4% (21/52) with placebo (adjusted risk difference, 18.4%; 95% CI, 0.3%-36.4%; P = .047). The proportion of patients with symptomatic intracranial hemorrhage within 24 hours was 0% with alteplase and 3.8% with placebo (risk difference, -3.8%; 95% CI, -13.2% to 2.5%). Ninety-day mortality was 8% with alteplase and 15% with placebo (risk difference, -7.2%; 95% CI, -19.2% to 4.8%). CONCLUSIONS AND RELEVANCE: Among patients with large vessel occlusion acute ischemic stroke and successful reperfusion following thrombectomy, the use of adjunct intra-arterial alteplase compared with placebo resulted in a greater likelihood of excellent neurological outcome at 90 days. However, because of study limitations, these findings should be interpreted as preliminary and require replication. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03876119; EudraCT Number: 2018-002195-40.
引用
- Renú A, Millán M, San Román L, et al. Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. JAMA. 2022. PMID: 35143603. doi:10.1001/jama.2022.1645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。